

March 5, 2026

Taiwan Meiji Pharma Launches REZUROCK® Tablets in Taiwan, a selective ROCK2 Inhibitor Indicated for the Treatment of cGVHD

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announces the launch of REZUROCK® Tablets (product name in Taiwan; INN: belumosudil), a selective Rho-associated, coiled-coil-containing protein kinase 2 (ROCK2) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD), effective March 5.

The product will be marketed by Taiwan Meiji Pharma Co., Ltd. (headquartered in Taipei City, Taiwan; Chairman: Kenshi Murase), a local subsidiary of Meiji Seika Pharma, on behalf of Romeck Pharma LLC, a joint venture between Meiji Seika Pharma and Kadmon Corporation LLC, a Sanofi company.

cGVHD presents a multifaceted challenge, with unmet medical needs spanning physical, emotional, and social realms. Physically, patients endure symptoms ranging from debilitating fatigue and chronic pain to organ dysfunction, which often persist long after allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). These enduring and deleterious features of cGVHD are driven by two major physiological responses, inflammation and fibrosis. cGVHD is the leading cause of non-relapse mortality and morbidity in patients who have undergone an allo-HSCT, with organ failure and infection as the leading causes ^{1,2}.

REZUROCK® is the first approved and only selective inhibitor of ROCK2, a kinase that plays a major role in signaling pathways regulating the body's inflammatory and fibrotic responses. It is commercially available by prescription to patients with cGVHD in several countries, including the United States, Canada, Great Britain, Japan, and South Korea. Romeck Pharma LLC has the exclusive rights to develop and commercialize REZUROCK® in Japan and 12 Asian countries.

Meiji Seika Pharma sincerely hopes that expanding access to REZUROCK®, a new treatment option, will benefit patients with cGVHD in Taiwan.

References

1. Salhotra, A., Eiznhamer D., Hennegan, K. et al (2020). Presentation and management of chronic graft-versus-host disease in real-world clinical practice: A medical chart audit. *EHA Virtual Congress*, Abstract EP1436
2. Filipovich, A., Weisdorf, D., Pavletic, S. et al (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biology of Blood and Marrow Transplantation*, 11(12): 945-956.